Human vascular ibp-like growth factor

Abstract

A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.

1 . An isolated polynucleotide comprising a member selected from the group consisting of:
 (a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2;   (b) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 163 as set forth in SEQ ID NO:2;   (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and   (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).   
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA. 
     
     
         3 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid −21 to amino acid 163 as set forth in SEQ ID NO:2. 
     
     
         4 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid 1 to amino acid 163 as set forth in SEQ ID NO:2. 
     
     
         5 . An isolated polynucleotide comprising a member selected from the group consisting of:
 (a) a polynucleotide which encodes a mature polypeptide encoded by the DNA contained in ATCC™ Deposit No. 75874;   (b) a polynucleotide which encodes a polypeptide expressed by the DNA contained in ATCC™ Deposit No. 75874;   (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and   (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).   
     
     
         6 . A vector containing the DNA of  claim 2 . 
     
     
         7 . A host cell genetically engineered with the vector of  claim 6 . 
     
     
         8 . A process for producing a polypeptide comprising expressing from the host cell of  claim 7  the polypeptide encoded by said DNA. 
     
     
         9 . A process for producing cells capable of expressing a polypeptide comprising transforming or transfecting the cells with the vector of  claim 6 . 
     
     
         10 . A polypeptide selected from the group consisting of:
 (a) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof;   (b) a polypeptide comprising amino acid 1 to amino acid 262 of SEQ ID NO:2; and   (c) a polypeptide encoded by the cDNA of ATCC™ Deposit No. 75874 and fragments, analogs and derivatives of said polypeptide.   
     
     
         11 . An isolated antibody or fragment thereof that specifically binds to the polypeptide of  claim 10 . 
     
     
         12 . A compound effective as an agonist for the polypeptide of  claim 10 . 
     
     
         13 . A compound effective as an antagonist against the polypeptide of  claim 10 . 
     
     
         14 . A method for the treatment of a patient having need of PGSG-1 comprising administering to the patient a therapeutically effective amount of the polypeptide of  claim 10 . 
     
     
         15 . The method of  claim 14  wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo. 
     
     
         16 . A method for the treatment of a patient having need of VIGF comprising administering to the patient a therapeutically effective amount of the compound of  claim 12 . 
     
     
         17 . A method for the treatment of a patient having need to inhibit VIGF comprising administering to the patient a therapeutically effective amount of the antagonist of  claim 13 . 
     
     
         18 . A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of  claim 10  comprising determining a mutation in the nucleic acid sequence encoding said polypeptide. 
     
     
         19 . A diagnostic process comprising analyzing for the presence of the polypeptide of  claim 10  in a sample derived from a host. 
     
     
         20 . A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of  claim 10  comprising:
 (a) contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and   (b) determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.